Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia
Status:
Recruiting
Trial end date:
2021-11-26
Target enrollment:
Participant gender:
Summary
To compare and evaluate the effects of LDL-C and Triglyceride (TG) control on the first dose
Ezetimibe/Statin (Rosuvastatin 5 mg/Ezetimibe 10 mg) combination therapy compared to the
average dose Statin (Rosuvastatin 10 mg) monotherapy in patients with Type 2 diabetes with
hypertriglyceridemia (TG > 200 mg/dL).